Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

To date, treatment with foralumab has shown promising results in stabilizing or improving clinical measures without serious adverse effects among patients with non-active secondary progressive multiple sclerosis.

FDA Allows Additional Enrollment to Foralumab Expanded Access Program 

ASPIRO, an open-label trial, will assess the safety and tolerability of ANPD001, an investigational autologous neuronal replacement therapy being studied as a regenerative therapy for PD.

Dosing Underway for Phase 1/2a Study of Autologous Cell Therapy ANPD001 in Parkinson Disease

Videos

Neurology News Network. for the week ending May 4, 2024. [WATCH TIME: 3 minutes]

ALZ-801 Enters Open-Label Studies, Subcutaneous Ocrelizumab Gets Positive EU Recommendation, FDA Approves Sprinkle Formulation of Valbenazine

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 3, 2024. 

NeurologyLive® Friday 5 — May 3, 2024

, has been with the team since October 2019. Follow him on Twitter 

The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology departments. [WATCH TIME: 4 minutes]

Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD

The chief scientific officer of the Parkinson’s Foundation and chief executive officer of Tasso discussed their company partnership to expand and accelerate genetic research in Parkinson Disease. [WATCH TIME: 6 minutes]

Using a Blood Collection Device to Advance Genetic Research in Parkinson Disease: James Beck, PhD & Ben Casavant, PhD

Director, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic 

The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]

Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD

The award ceremony is supported by EMD Serono and Viatris and will take place on Thursday, May 30, 2024, at the Nashville Music City Center in Nashville, Tennessee, during the 2024 CMSC Annual Meeting.

NeurologyLive and CMSC Announce the 3rd Annual Giants of MS Class of Inductees

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

Authors

Associate professor of chemistry at Vanderbilt University and the inaugural Dorothy J. Wingfield Phillips Chancellor’s Faculty Fellow.

The full professor of chemistry at Vanderbilt University talked about research surrounding racial and ethnic disparities in Alzheimer disease incidence. [WATCH TIME: 5 minutes]

Insights on Addressing Disparities in Alzheimer Disease Research: Renã A. S. Robinson, PhD